Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>Products>This Product
  Products


Adaptable Semi-Automatic Microplate Sealer

Product Image
Product Description

The MiniSeal II semi-automatic microplate sealer from Porvair Sciences comes complete with adapters enabling it to process deep well, shallow well, low profile deep well, filter and assay plates that conform to the ANSI / SLAS standard format. MiniSeal II plate adaptors not currently in use are ingeniously designed to stack on top of the unit to keep them readily available.

The MiniSeal II heat sealer operates with a very high force, this together with a powerful 450W heater ensures high integrity sealing of almost any type of microplate. With so much available power, sealing times for most polypropylene plates with Porvair seals are less than 3 seconds each. Sealed plates are automatically ejected from the MiniSeal II. The compact footprint, about the size of a sheet of A4 paper, means that MiniSeal II will fit just about anywhere - on your lab bench or inside a fumehood if required.

Easy to set up with simple up/down programming for both sealing time and sealing temperature, the MiniSeal II includes a robust microplate insertion drawer design that ensures excellent conformance to health and safety regulations. Designed for ease-of-use and installation the compact MiniSeal II just requires plugging into a single electrical outlet to operate. Unlike larger and more expensive automated sealers the MiniSeal II does not require a compressed air supply to operate.

Product Adaptable Semi-Automatic Microplate Sealer
Company Porvair Sciences
Price Request a quote
More Information View company product page
Catalog Number Unspecified
Quantity Unspecified
Company Logo

Porvair Sciences
Porvair Sciences Limited Dorset House Regent Park Kingston Road Leatherhead KT22 7PL

Tel: +44 (0) 1372 824290
Fax: +44 (0) 1372 824271
Email: int.sales@porvair-sciences.com



Scientific News
Spero Therapeutics Announces $30 Million Series B Preferred Financing
Company has announced financing of $30 million to support development of novel therapies to treat gram-negative bacterial infections.
Keeping Tumor Growth at Bay
Engineers at Washington University in St. Louis found a way to keep a cancerous tumor from growing by using nanoparticles of the main ingredient in common antacid tablets.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
Improving Delivery of Poorly Soluble Drugs Using Nanoparticles
A technology that could forever change the delivery of drugs is undergoing evaluation by the Technology Evaluation Consortium™ (TEC). Developed by researchers at Northeastern University, the technology is capable of creating nanoparticle structures that could deliver drugs into the bloodstream orally – despite the fact that they are normally poorly soluble.
Faster Drug Discovery?
Startup develops more cost-effective test for assessing how cells respond to chemicals.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Nanoparticles Deliver Tumor Suppressors to Damaged Livers
UT Southwestern Medical Center chemists have successfully used synthetic nanoparticles to deliver tumor-suppressing therapies to diseased livers with cancer, an important hurdle scientists have been struggling to conquer.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
A New Type of Anticancer Agent
Success in the development of a ?-tubulin specific inhibitor.
Nanoparticles Proven Effective Against Antibiotic-Resistant “Superbugs”
In the ever-escalating evolutionary battle with drug-resistant bacteria, humans may soon have a leg up thanks to adaptive, light-activated nanotherapy developed by researchers at the University of Colorado Boulder.

SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!